Weight Loss & Diabetes Market Scoreboard Today: Lilly vs Novo

Weight loss and diabetes market scoreboard action heats up today as Eli Lilly’s and Novo Nordisk trade sharp punches in the high-stakes GLP-1 arena.

Lilly delivers striking late-stage weight-loss results from its experimental drug in people with type 2 diabetes and claims clear advantages for its oral Foundayo over Novo’s higher-dose oral semaglutide on both weight reduction and blood-sugar control.

Novo answers with real-world evidence showing that patients who escalate their Ozempic dose face a lower risk of major cardiovascular events than those who switch to Lilly’s Mounjaro.

These dual-market updates create a vivid scoreboard day: Lilly presses efficacy and oral convenience in weight loss plus diabetes while Novo defends its cardiovascular outcomes leadership.

Investors and clinicians now watch every data point as the two giants battle for dominance in a market racing toward massive scale.

Scoreboard Highlights: Three Key Updates

• Lilly’s experimental drug drives nearly 21 percent average body-weight reduction in a late-stage trial of adults with type 2 diabetes and obesity.
• Lilly’s oral Foundayo outperforms Novo’s higher-dose oral semaglutide on both weight loss and A1C in an indirect comparison drawn from existing studies.
• Novo’s real-world analysis finds that escalating Ozempic delivers a statistically significant lower risk of major cardiovascular events versus switching to Lilly’s Mounjaro.

Lilly’s Experimental Drug Delivers Nearly 21% Weight Loss

Eli Lilly reports that its experimental drug helped adults with type 2 diabetes and obesity lose an average of nearly 21 percent of their body weight in a late-stage clinical trial. The company released the data on Tuesday, underscoring the candidate’s potential in the crowded weight-loss and diabetes space.

Patients entered the study carrying both conditions, and the results position the medicine as a potent option for clinicians seeking substantial body-weight reduction alongside diabetes management.

Also Read: 10 GLP-1 Drugs Revolutionizing Diabetes & Obesity Treatment

Lilly Claims Foundayo Edge Over Novo’s Oral Semaglutide

Eli Lilly states that its oral obesity drug Foundayo produces greater weight loss and better blood-sugar control than a higher dose of Novo Nordisk’s Ozempic pill in adults with type 2 diabetes. The company bases the claim on an indirect comparison of Foundayo’s 17.2-milligram dose against Novo’s 25-mg oral semaglutide, drawing from two previous late-stage studies.

Key findings from Lilly’s analyses:

• Foundayo 17.2 mg shows 1.5 percent to 2.4 percent greater weight loss than oral semaglutide 25 mg
• Foundayo delivers 0.3 percent to 0.6 percent larger reductions in A1C
• Different statistical methods produce consistent results across the comparisons

Rachel Batterham, senior vice president of medical innovation and external engagement at Lilly Cardiometabolic Health, notes that head-to-head trials ultimately supply the best comparison of two medicines, yet other approaches can still provide informative data points when those trials remain unavailable.

Additional context:

• Novo’s 25 mg once-daily dose of oral semaglutide has not received U.S. approval for type 2 diabetes
• The Danish company expects an FDA decision by the end of 2026
• A Novo spokesperson emphasizes that the indirect comparison involves people with type 2 diabetes rather than those with obesity alone
• Patients with type 2 diabetes typically lose less weight in clinical studies

Ozempic pill contains semaglutide, the same active ingredient found in Novo’s Wegovy. Both belong to the GLP-1 class that regulates blood sugar and suppresses appetite. Lilly and Novo continue racing to defend and expand their positions as rivals push next-generation treatments that promise greater convenience, tolerability, and effectiveness.

Also Read: World Heart Day 2026: 8 Ways to Protect Your Heart Every Day

Novo Counters with Cardiovascular Real-World Data

Novo Nordisk reports that a real-world study found adults with type 2 diabetes who escalated their dose of Ozempic faced a lower risk of major cardiovascular events compared with those who switched to Eli Lilly’s Mounjaro. The company presented the findings at the European Association for the Study of Diabetes annual meeting in Milan.

Core results:

• Patients who moved from Ozempic 1 mg to 2 mg experienced a statistically significant 6 percent lower risk of major adverse cardiovascular events
• The comparison group switched to Mounjaro doses of up to 15 mg

Study details on 636,525 adults:

• Within 365 days of first prescription: 67.2 percent remained on Ozempic 1 mg; 29.2 percent either increased to Ozempic 2 mg or switched to Mounjaro
• At the 720-day follow-up: 57.4 percent stayed on Ozempic 1 mg; 36.9 percent escalated to 2 mg; 5.7 percent had switched to Mounjaro

Michael Radin, executive medical director at Novo, states that these real-world findings can help provide insights into how intensification strategies may affect cardiovascular outcomes as an important factor in patient care.

The data build on an earlier analysis of the same cohort that examined HbA1c and weight loss. Novo and Lilly remain locked in a fierce battle for dominance in the U.S. obesity drug market, which analysts expect to reach between USD 100 billion and USD 150 billion by 2030.

Today’s scoreboard therefore shows Lilly advancing on pure efficacy and oral convenience while Novo reinforces its cardiovascular credentials. Both companies keep trading blows, and the next data releases will decide who claims the next points in this high-stakes contest.